Antiviral efficacy of a respiratory syncytial virus (RSV) fusion inhibitor in a bovine model of RSV infection

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 4889-4900

  Jordan, Robert ^a   Shao, Matt ^b   Mackman, Richard L ^a   Perron, Michel ^a   Cihlar, Tomas ^a   Lewis, Sandy A ^a   Eisenberg, Eugene J ^a   Carey, Anne ^a   Strickley, Robert G ^a   Chien, Jason W ^a   Anderson, Mark L ^b   McEligot, Heather A ^b   Behrens, Nicole E ^b   Gershwin, Laurel J ^b  

^a GILEAD SCIENCES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GS 1; HUMAN RESPIRATORY SYNCYTIAL VIRUS FUSION INHIBITOR; UNCLASSIFIED DRUG; VIRUS FUSION INHIBITOR; ANTIVIRUS AGENT; GS-5806; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BOVINE MODEL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; HISTOPATHOLOGY; HOST CELL; IN VITRO STUDY; LUNG LAVAGE; LUNG PARENCHYMA; MALE; MEAN RESIDENCE TIME; NONHUMAN; NOSE SECRETION; NOSE SMEAR; PHYSICAL EXAMINATION; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS LOAD; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANIMAL; BOVINE; BOVINE RESPIRATORY SYNCYTIAL VIRUS; BRONCHIOLITIS; CATTLE DISEASES; CELL LINE; CELL MEMBRANE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; LUNG; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; BRONCHIOLITIS; CATTLE; CATTLE DISEASES; CELL LINE; CELL MEMBRANE; DOUBLE-BLIND METHOD; HUMANS; LUNG; MALE; PYRAZOLES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, BOVINE; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SULFONAMIDES; VIRAL LOAD;

EID: 84939856984     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00487-15     Document Type: Article

References (44)

1. Neilson KA, Yunis EJ. 1990. Demonstration of respiratory syncytial virus in an autopsy series. Pediatr Pathol 10:491-502. http://dx.doi.org/10.3109/15513819009067138.
2. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. 2002. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 76:5654-5666. http://dx.doi.org/10.1128/JVI.76.11.5654-5666.2002.
3. Ioannidis I, McNally B, Willette M, Peeples ME, Chaussabel D, Durbin JE, Ramilo O, Mejias A, Flano E. 2012. Plasticity and virus specificity of the airway epithelial cell immune response during respiratory virus infection. J Virol 86:5422-5436. http://dx.doi.org/10.1128/JVI.06757-11.
4. Borchers AT, Chang C, Gershwin ME, Gershwin LJ. 2013. Respiratory syncytial virus-a comprehensive review. Clin Rev Allergy Immunol 45:331-379. http://dx.doi.org/10.1007/s12016-013-8368-9.
5. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. 2009. The burden of respiratory syncytial virus infection in young children. N Engl J Med 360:588-598. http://dx.doi.org/10.1056/NEJMoa0804877.
6. Falsey AR. 2005. Respiratory syncytial virus infection in elderly and high-risk adults. Exp Lung Res 31(Suppl 1):77.
7. Waghmare A, Campbell AP, Xie H, Seo S, Kuypers J, Leisenring W, Jerome KR, Englund JA, Boeckh M. 2013. Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. Clin Infect Dis 57:1731-1741. http://dx.doi.org/10.1093/cid/cit639.
8. Jackson DJ, Lemanske RF, Jr. 2010. The role of respiratory virus infections in childhood asthma inception. Immunol Allergy Clin North Am 30:513-522. http://dx.doi.org/10.1016/j.iac.2010.08.004.
9. Busse WW, Lemanske RF, Jr, Gern JE. 2010. Role of viral respiratory infections in asthma and asthma exacerbations. Lancet 376:826-834. http://dx.doi.org/10.1016/S0140-6736(10)61380-3.
10. Wedzicha JA. 2004. Role of viruses in exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 1:115-120. http://dx.doi.org/10.1513/pats.2306030.
11. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. 2005. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352:1749-1759. http://dx.doi.org/10.1056/NEJMoa043951.
12. Romero JR. 2003. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr Infect Dis J 22(Suppl 2):S46-S54. http://dx.doi.org/10.1097/00006454-200302001-00007.
13. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89:422-434.
14. American Academy of Pediatrics Committee on Infectious Diseases. 1993. Use of ribavirin in the treatment of respiratory syncytial virus infection. Pediatrics 92:501-504.
15. Shah DP, Ghantoji SS, Shah JN, El Taoum KK, Jiang Y, Popat U, Hosing C, Rondon G, Tarrand JJ, Champlin RE, Chemaly RF. 2013. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother 68:1872-1880. http://dx.doi.org/10.1093/jac/dkt111.
16. Seo S, Campbell AP, Xie H, Chien JW, Leisenring WM, Englund JA, Boeckh M. 2013. Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement. Biol Blood Marrow Transplant 19:589-596. http://dx.doi.org/10.1016/j.bbmt.2012.12.019.
17. Olszewska W, Ispas G, Schnoeller C, Sawant D, Van de Casteele T, Nauwelaers D, Van Kerckhove B, Roymans D, De Meulder M, Rouan MC, Van Remoortere P, Bonfanti JF, Van Velsen F, Koul A, Vanstockem M, Andries K, Sowinski P, Wang B, Openshaw P, Verloes R. 2011. Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur Respir J 38:401-408. http://dx.doi.org/10.1183/09031936.00005610.
18. Cianci C, Genovesi EV, Lamb L, Medina I, Yang Z, Zadjura L, Yang H, D'Arienzo C, Sin N, Yu KL, Combrink K, Li Z, Colonno R, Meanwell N, Clark J, Krystal M. 2004. Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob Agents Chemother 48:2448-2454. http://dx.doi.org/10.1128/AAC.48.7.2448-2454.2004.
19. Wyde PR, Laquerre S, Chetty SN, Gilbert BE, Nitz TJ, Pevear DC. 2005. Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol. Antiviral Res 68:18-26. http://dx.doi.org/10.1016/j.antiviral.2005.06.009.
20. DeVincenzo J, Whitley RJ, Scaglioni C, Harrison L, Farrell E, McBride S, Mackman RL, Jordan R, Xin Y, Ramanathan S, O'Riordan T, Lewis SA, Li X, Toback SL, Lin SL, Chien JW. 2014. Oral GS-5806 reduces viral load and clinical symptoms in a respiratory syncytial virus challenge study. N Engl J Med 371:711-722. http://dx.doi.org/10.1056/NEJMoa1401184.
21. Henderson EA, Alber DG, Baxter RC, Bithell SK, Budworth J, Carter MC, Chubb A, Cockerill GS, Dowdell VC, Fraser IJ, Harris RA, Keegan SJ, Kelsey RD, Lumley JA, Stables JN, Weerasekera N, Wilson LJ, Powell KL. 2007. 1,4-Benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate. J Med Chem 50:1685-1692.
22. Sudo K, Miyazaki Y, Kojima N, Kobayashi M, Suzuki H, Shintani M, Shimizu Y. 2005. YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action. Antiviral Res 65:125-131. http://dx.doi.org/10.1016/j.antiviral.2004.12.002.
23. Liuzzi M, Mason SW, Cartier M, Lawetz C, McCollum RS, Dansereau N, Bolger G, Lapeyre N, Gaudette Y, Lagace L, Massariol MJ, Do F, Whitehead P, Lamarre L, Scouten E, Bordeleau J, Landry S, Rancourt J, Fazal G, Simoneau B. 2005. Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase. J Virol 79:13105-13115. http://dx.doi.org/10.1128/JVI.79.20.13105-13115.2005.
24. Prince GA, Jenson AB, Horswood RL, Camargo E, Chanock RM. 1978. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol 93:771-791.
25. Boukhvalova MS, Prince GA, Blanco JC. 2009. The cotton rat model of respiratory viral infections. Biologicals 37:152-159. http://dx.doi.org/10.1016/j.biologicals.2009.02.017.
26. Bem RA, Domachowske JB, Rosenberg HF. 2011. Animal models of human respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol 301:L148-L156. http://dx.doi.org/10.1152/ajplung.00065.2011.
27. Derscheid RJ, Ackermann MR. 2012. Perinatal lamb model of respiratory syncytial virus (RSV) infection. Viruses 4:2359-2378. http://dx.doi.org/10.3390/v4102359.
28. Eyles JE, Johnson JE, Megati S, Roopchand V, Cockle PJ, Weeratna R, Makinen S, Brown TP, Lang S, Witko SE, Kotash CS, Li J, West K, Maldonado O, Falconer DJ, Lees C, Smith GJ, White P, Wright P, Loudon PT, Merson JR, Jansen KU, Sidhu MK. 2013. Nonreplicating vaccines can protect African green monkeys from the Memphis 37 strain of respiratory syncytial virus. J Infect Dis 208:319-329. http://dx.doi.org/10.1093/infdis/jit169.
29. Vaughan K, Rhodes GH, Gershwin LJ. 2005. DNA immunization against respiratory syncytial virus (RSV) in infant rhesus monkeys. Vaccine 23:2928-2942. http://dx.doi.org/10.1016/j.vaccine.2004.10.046.
30. Derscheid RJ, van Geelen A, Gallup JM, Kienzle T, Shelly DA, Cihlar T, King RR, Ackermann MR. 2014. Human respiratory syncytial virus Memphis 37 causes acute respiratory disease in perinatal lamb lung. Biores Open Access 3:60-69. http://dx.doi.org/10.1089/biores.2013.0044.
31. Elazhary MA, Galina M, Roy RS, Fontaine M, Lamothe P. 1980. Experimental infection of calves with bovine respiratory syncytial virus (Quebec strain). Can J Comp Med 44:390-395.
32. Gershwin LJ, Anderson ML, Wang C, Berghaus LJ, Kenny TP, Gunther RA. 2011. Assessment of IgE response and cytokine gene expression in pulmonary efferent lymph collected after ovalbumin inhalation during experimental infection of calves with bovine respiratory syncytial virus. Am J Vet Res 72:134-145. http://dx.doi.org/10.2460/ajvr.72.1.134.
33. Valarcher JF, Taylor G. 2007. Bovine respiratory syncytial virus infection. Vet Res 38:153-180. http://dx.doi.org/10.1051/vetres:2006053.
34. Gershwin LJ, Schelegle ES, Gunther RA, Anderson ML, Woolums AR, Larochelle DR, Boyle GA, Friebertshauser KE, Singer RS. 1998. A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology. Vaccine 16:1225-1236. http://dx.doi.org/10.1016/S0264-410X(98)80123-0.
35. Zekarias B, Mattoo S, Worby C, Lehmann J, Rosenbusch RF, Corbeil LB. 2010. Histophilus somni IbpA DR2/Fic in virulence and immunoprotection at the natural host alveolar epithelial barrier. Infect Immun 78:1850-1858. http://dx.doi.org/10.1128/IAI.01277-09.
36. Gershwin LJ, Berghaus LJ, Arnold K, Anderson ML, Corbeil LB. 2005. Immune mechanisms of pathogenetic synergy in concurrent bovine pulmonary infection with Haemophilus somnus and bovine respiratory syncytial virus. Vet Immunol Immunopathol 107:119-130. http://dx.doi.org/10.1016/j.vetimm.2005.04.004.
37. Berghaus LJ, Corbeil LB, Berghaus RD, Kalina WV, Kimball RA, Gershwin LJ. 2006. Effects of dual vaccination for bovine respiratory syncytial virus and Haemophilus somnus on immune responses. Vaccine 24:6018-6027. http://dx.doi.org/10.1016/j.vaccine.2006.03.077.
38. US Interagency Research Animal Committee. 1991. Principles for the utilization and care of vertebrate animals used in testing, research, and training. National Academies Press, Washington, DC.
39. th ed. National Academies Press, Washington, DC.
40. US Congress. 1966. Public Law 89-544 Act of August 24, 1966. United States Code, Title 7, Sections 2131-2156.
41. Walter MJ, Castro M, Kunselman SJ, Chinchilli VM, Reno M, Ramkumar TP, Avila PC, Boushey HA, Ameredes BT, Bleecker ER, Calhoun WJ, Cherniack RM, Craig TJ, Denlinger LC, Israel E, Fahy JV, Jarjour NN, Kraft M, Lazarus SC, Lemanske RF, Jr, Martin RJ, Peters SP, Ramsdell JW, Sorkness CA, Sutherland ER, Szefler SJ, Wasserman SI, Wechsler ME. 2008. Predicting worsening asthma control following the common cold. Eur Respir J 32:1548-1554. http://dx.doi.org/10.1183/09031936.00026808.
42. Ricart S, Marcos MA, Sarda M, Anton A, Munoz-Almagro C, Pumarola T, Pons M, Garcia-Garcia JJ. 2013. Clinical risk factors are more relevant than respiratory viruses in predicting bronchiolitis severity. Pediatr Pulmonol 48:456-463. http://dx.doi.org/10.1002/ppul.22633.
43. Mackman RL, Sangi M, Sperandio D, Parrish JP, Eisenberg E, Perron M, Hui H, Zhang L, Siegel D, Yang H, Saunders O, Boojamra C, Lee G, Samuel D, Babaoglu K, Carey A, Gilbert BE, Piedra PA, Strickley R, Iwata Q, Hayes J, Stray K, Kinkade A, Theodore D, Jordan R, Desai MC, Cihlar T. 2015. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem 58:1630-1643. http://dx.doi.org/10.1021/jm5017768.
44. Sacco RE, McGill JL, Pillatzki AE, Palmer MV, Ackermann MR. 2014. Respiratory syncytial virus infection in cattle. Vet Pathol 51:427-436. http://dx.doi.org/10.1177/0300985813501341.